GANX · Gain Therapeutics, Inc. · Analyst Estimates
$1.64
+0.03 (+1.55%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”View the 10-Q filed Aug 11, 2026
Market Cap
$71.58M
Shares
43.64M
Volume · Oct 9
328.69K
Avg daily vol (3M)
491.88K
Analyst Estimates
Compare analyst forecasts for Gain Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-10-07 10:24 UTC · Publication dates shown per estimate · 16 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.53
|
-0.505
|
-0.48
|
— |
-0.49667
|
-0.6025
|
-0.49667
|
-0.6025
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
4
|
— | — | — | — |
0
|
0
|
3
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.11
|
-0.6875
|
-0.49
|
— |
-0.54667
|
-0.6
|
-0.54667
|
-0.6
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
4
|
— | — | — | — |
1
|
1
|
2
|
0
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.13
|
-0.1275
|
-0.12
|
— |
-0.12667
|
-0.1575
|
-0.12667
|
-0.1575
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
4
|
— | — | — | — |
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.16
|
-0.135
|
-0.11
|
— |
-0.12667
|
-0.155
|
-0.12667
|
-0.155
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
4
|
— | — | — | — |
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |